Newsroom

Oct 12, 2026 FungiFlex Editor’s Choice Article: Journal of Fungi Selects University of Minnesota and Zepto Life Technology Study Findings highlight the potential of plasma fungal cell-free DNA testing to support diagnosis of infections in and beyond the lungs. → Aug 10, 2026 MDx NIAID Awards Zepto Life Technology Contract Valued at Up to $8.9 Million to Advance the First Deployable Liquid Biopsy Platform for Infectious Disease Award funds Zepto’s FungiFlex® program from engineering and manufacturing through planned clinical validation and FDA submission. → Aug 3, 2026 FungiFlex Zepto Presents ADLM Case Highlighting Detection of a Mixed Invasive Mold Infection from Plasma At ADLM 2026, Zepto Life Technology presented a case in which the FungiFlex® Mold Panel detected fungal cell-free DNA from Aspergillus fumigatus and Rhizomucor miehei in an immunocompromised patient, revealing a mixed invasive mold infection that standard testing alone did not fully identify. → Jul 15, 2026 FungiFlexReference lab Zepto Life Technology Introduces FungiFlex® Pneumocystis jirovecii and FungiFlex® Mold Plus New targeted plasma cfDNA liquid biopsy testing options expand the FungiFlex® menu, allowing clinicians to order targeted Pneumocystis jirovecii testing or combined mold and P. jirovecii detection based on the clinical question. → Jun 15, 2026 FungiFlex New Journal of Fungi Publication Features Zepto FungiFlex® in Pneumocystis Case Series A University of Minnesota collaboration examines how plasma fungal cfDNA testing can help distinguish active infection from colonization in complex, immunocompromised patients. → Jun 3, 2026 FungiFlex Zepto Life Technology Receives FDA Breakthrough Device Designation for Targeted Liquid Biopsy Test for Invasive Mold Infections The designation applies to the FungiFlex® Mold Panel performed on Zepto's integrated MDx instrument system, recognizing its potential to address a significant unmet need in invasive mold infection diagnosis. →